JP2015532281A - 複数キナーゼ経路阻害剤 - Google Patents

複数キナーゼ経路阻害剤 Download PDF

Info

Publication number
JP2015532281A
JP2015532281A JP2015534612A JP2015534612A JP2015532281A JP 2015532281 A JP2015532281 A JP 2015532281A JP 2015534612 A JP2015534612 A JP 2015534612A JP 2015534612 A JP2015534612 A JP 2015534612A JP 2015532281 A JP2015532281 A JP 2015532281A
Authority
JP
Japan
Prior art keywords
dialkylamino
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015534612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532281A5 (enExample
Inventor
チンピン ゼン，
チンピン ゼン，
マリー ファリス，
マリー ファリス，
アレクシス モラード，
アレクシス モラード，
スティーブン エル． ワーナー，
スティーブン エル． ワーナー，
ゲイリー エー． フリン，
ゲイリー エー． フリン，
Original Assignee
マンカインド コーポレイション
マンカインド コーポレイション
トレロ ファーマシューティカルズ， インコーポレイテッド
トレロ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション, マンカインド コーポレイション, トレロ ファーマシューティカルズ， インコーポレイテッド, トレロ ファーマシューティカルズ， インコーポレイテッド filed Critical マンカインド コーポレイション
Publication of JP2015532281A publication Critical patent/JP2015532281A/ja
Publication of JP2015532281A5 publication Critical patent/JP2015532281A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015534612A 2012-09-26 2013-09-25 複数キナーゼ経路阻害剤 Pending JP2015532281A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261706084P 2012-09-26 2012-09-26
US61/706,084 2012-09-26
US201361757331P 2013-01-28 2013-01-28
US61/757,331 2013-01-28
US201361785992P 2013-03-14 2013-03-14
US61/785,992 2013-03-14
PCT/US2013/061548 WO2014052365A1 (en) 2012-09-26 2013-09-25 Multiple kinase pathway inhibitors

Publications (2)

Publication Number Publication Date
JP2015532281A true JP2015532281A (ja) 2015-11-09
JP2015532281A5 JP2015532281A5 (enExample) 2016-11-17

Family

ID=50388917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534612A Pending JP2015532281A (ja) 2012-09-26 2013-09-25 複数キナーゼ経路阻害剤

Country Status (8)

Country Link
US (2) US9493454B2 (enExample)
EP (1) EP2900668A4 (enExample)
JP (1) JP2015532281A (enExample)
CN (1) CN104812756A (enExample)
AU (1) AU2013323736A1 (enExample)
CA (1) CA2886275A1 (enExample)
HK (1) HK1212683A1 (enExample)
WO (1) WO2014052365A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510083A (ja) * 2016-12-16 2020-04-02 シーストーン・ファーマスーティカルズＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｄｋ４／６阻害剤

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
WO2014052365A1 (en) * 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
CN104418853B (zh) * 2013-08-28 2016-09-07 北大方正集团有限公司 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
RU2752729C2 (ru) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
AU2019247498A1 (en) 2018-04-05 2020-11-26 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
WO2019200254A1 (en) 2018-04-13 2019-10-17 Tolero Pharmaceuticals, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
MX2021005075A (es) * 2018-12-07 2021-07-15 Sumitomo Pharma Oncology Inc Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515078A (ja) * 1997-08-20 2001-09-18 ワーナー−ランバート・カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
JP2007508310A (ja) * 2003-10-08 2007-04-05 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
WO2014052365A1 (en) * 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515078A (ja) * 1997-08-20 2001-09-18 ワーナー−ランバート・カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
JP2007508310A (ja) * 2003-10-08 2007-04-05 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510083A (ja) * 2016-12-16 2020-04-02 シーストーン・ファーマスーティカルズＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｄｋ４／６阻害剤
JP7044801B2 (ja) 2016-12-16 2022-03-30 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド Ｃｄｋ４／６阻害剤

Also Published As

Publication number Publication date
HK1212683A1 (zh) 2016-06-17
US9493454B2 (en) 2016-11-15
US20170107215A1 (en) 2017-04-20
US9714247B2 (en) 2017-07-25
AU2013323736A1 (en) 2015-04-09
EP2900668A4 (en) 2016-04-20
WO2014052365A1 (en) 2014-04-03
CN104812756A (zh) 2015-07-29
US20150266870A1 (en) 2015-09-24
CA2886275A1 (en) 2014-04-03
EP2900668A1 (en) 2015-08-05
AU2013323736A8 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
JP2015532281A (ja) 複数キナーゼ経路阻害剤
KR102797536B1 (ko) PI3Kα 억제제 및 이의 사용 방법
JP6475158B2 (ja) Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
TWI839363B (zh) 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物
CA2868156C (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
TW201831483A (zh) Ｆｇｆｒ抑制劑及其應用
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
US10870639B2 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US8912181B2 (en) Bicyclic compound or salt thereof
CN110872296A (zh) 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
WO2023039532A1 (en) Pi3k-alpha inhibitors and methods of use thereof
WO2022272106A1 (en) Cdk2 inhibitors and methods of using the same
CN111153891A (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
JP2018513214A (ja) 新規なキナーゼ阻害剤の調製と使用
CN113840823B (zh) 显示癌细胞生长抑制效果的新型杂环取代的嘧啶衍生物，以及包含其的药物组合物
RU2807277C2 (ru) Соединения пиримидина и содержащие их фармацевтические композиции для предупреждения или лечения рака
WO2023109540A1 (zh) 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
AU2023380028A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
WO2024104244A1 (zh) 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途
KR20240054994A (ko) AhR 시그널링의 조절에 유용한 화합물
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK40009843A (en) Fgfr inhibitor and application thereof
HK1255833B (en) Hpk1 inhibitors and methods of using same
HK1255833A1 (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180320